Cargando…
How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?
BACKGROUND: One of the questions in the design of cancer clinical trials with combination of two drugs is in which order to administer the drugs. This is an important question, especially in the case where one agent may interfere with the effectiveness of the other agent. RESULTS: In the present pap...
Autores principales: | Lai, Xiulan, Friedman, Avner |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427900/ https://www.ncbi.nlm.nih.gov/pubmed/30894166 http://dx.doi.org/10.1186/s12918-019-0706-y |
Ejemplares similares
-
Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017) -
Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model
por: Friedman, Avner, et al.
Publicado: (2018) -
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model
por: Lai, Xiulan, et al.
Publicado: (2017) -
TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model
por: Lai, Xiulan, et al.
Publicado: (2020) -
Exosomal miRs in Lung Cancer: A Mathematical Model
por: Lai, Xiulan, et al.
Publicado: (2016)